Non-Small Cell Lung Cancer Treatment Market Size, Share, Growth, Trends, and Industry Analysis: By Drug Class, By Application Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, and Others), By Distribution Channel, and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Non-Small Cell Lung Cancer (NSCLC) Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: Size, Share, Growth, Trends, and Industry Analysis By Drug Class (Angiogenesis Inhibitors, Epidermal Growth Factor Receptor Blockers, Kinase Inhibitors, Microtubule Stabilizers, Folate Antimetabolites, and PD-1/ PD-L1 Inhibitors), By Application (Large Cell (Undifferentiated) Carcinoma, Squamous Cell (Epidermoid) Carcinoma, Adenocarcinoma, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Non Small Cell Lung Cancer Nsclc Treatment Market size was valued at US$ 12.3 billion in 2023 and is poised to grow at a CAGR of 9.6% from 2024 to 2030. Lung cancer usually starts when cells of the lung become abnormal and begin to grow out of control. With the uncontrolled growth of the cancer cells, forms the tumor which tends to spread to other parts of the body. There are two types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 80% to 85% of lung cancers are non-small cell lung cancer (NSCLC), whereas 10% to 15% are small cell lung cancer (SCLC).

Non-small cell lung cancer (NSCLC) is a cell lining air passage, characterized by abnormal cell growth in lung tissue. Depending on the stage of the cancer, there are various treatment options that are available, which include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Key developments in market In February 2018, AstraZeneca and MedImmune, its global biologics research and development arm, announced that the US Food and Drug Administration (FDA) has approved Imfinzi for the treatment of patients with unresectable Stage III non-small-cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

summary download arrow Download Free Sample

Non Small Cell Lung Cancer Nsclc Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

9.6%

Largest Market

North America

Fastest Growing Market

Europe

Non Small Cell Lung Cancer Nsclc Treatment Market Dynamics

Increase in the prevalence of lung cancer is majorly driving the non-small cell lung cancer (NSCLC) treatment market. The growing awareness about the lung cancer diagnosis, treatment and the support from the government organizations expected to enhance the growth of the market. The adoption of the unhealthy lifestyle is also adding fuel for to the growth of the market.

According to the American lung association, the number of deaths due to lung cancer has increased 3.5% from 152,156 cases in 1999 to 157,499 in 2012 and according to American Society of cancer, non-small cell lung cancer accounts for 85% to 90% of overall lung cancer cases. Owing to the larger patient pool, the market is expected to exhibit growth over the forecast period. However, the limited treatment options, and the availability of the generic drugs are likely to hinder the growth of the market.

Non Small Cell Lung Cancer Nsclc Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 12.3 billion

Market CAGR

9.6%

By Drug Class

  • Microtubule Stabilizer
  • Angiogenesis Inhibitors
  • Kinase Inhibitor
  • Epidermal Growth Factor Receptor Blocker
  • PD-1/ PD-L1 Inhibitor
  • Folate Antimetabolites

By Application

  • Large Cell (Undifferentiated) Carcinoma
  • Squamous Cell (Epidermoid) Carcinoma
  • Adenocarcinoma
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Key Features of the Report

  • The non small cell lung cancer nsclc treatment market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startups details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The global non small cell lung cancer nsclc treatment market size was valued at US$ 12.3 billion in 2023 and is projected to grow at a CAGR of 9.6% by 2030.

The non-small cell lung cancer (nsclc) treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The non-small cell lung cancer (nsclc) treatment market key players are: Bristol-Myers Squibb (U.S), AstraZeneca plc (U.K), Celgene Corporation (U.S), Boehringer Ingelheim (Germany), Novartis AG (Switzerland)

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Non Small Cell Lung Cancer Nsclc Treatment Market Introduction 
2.1.Global Non Small Cell Lung Cancer Nsclc Treatment Market  - Taxonomy
2.2.Global Non Small Cell Lung Cancer Nsclc Treatment Market  - Definitions
2.2.1.Drug Class
2.2.2.Application
2.2.3.Distribution Channel
2.2.4.Region
3. Global Non Small Cell Lung Cancer Nsclc Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Non Small Cell Lung Cancer Nsclc Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Non Small Cell Lung Cancer Nsclc Treatment Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Microtubule Stabilizer
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Angiogenesis Inhibitors
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Kinase Inhibitor
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Epidermal Growth Factor Receptor Blocker
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. PD-1/ PD-L1 Inhibitor
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Folate Antimetabolites
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6. Global Non Small Cell Lung Cancer Nsclc Treatment Market  By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Large Cell (Undifferentiated) Carcinoma
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Squamous Cell (Epidermoid) Carcinoma
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Adenocarcinoma
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Non Small Cell Lung Cancer Nsclc Treatment Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Non Small Cell Lung Cancer Nsclc Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Non Small Cell Lung Cancer Nsclc Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Microtubule Stabilizer
9.1.2.Angiogenesis Inhibitors
9.1.3.Kinase Inhibitor
9.1.4.Epidermal Growth Factor Receptor Blocker
9.1.5.PD-1/ PD-L1 Inhibitor
9.1.6.Folate Antimetabolites
9.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Large Cell (Undifferentiated) Carcinoma
9.2.2.Squamous Cell (Epidermoid) Carcinoma
9.2.3.Adenocarcinoma
9.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Non Small Cell Lung Cancer Nsclc Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Microtubule Stabilizer
10.1.2.Angiogenesis Inhibitors
10.1.3.Kinase Inhibitor
10.1.4.Epidermal Growth Factor Receptor Blocker
10.1.5.PD-1/ PD-L1 Inhibitor
10.1.6.Folate Antimetabolites
10.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Large Cell (Undifferentiated) Carcinoma
10.2.2.Squamous Cell (Epidermoid) Carcinoma
10.2.3.Adenocarcinoma
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Non Small Cell Lung Cancer Nsclc Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Microtubule Stabilizer
11.1.2.Angiogenesis Inhibitors
11.1.3.Kinase Inhibitor
11.1.4.Epidermal Growth Factor Receptor Blocker
11.1.5.PD-1/ PD-L1 Inhibitor
11.1.6.Folate Antimetabolites
11.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Large Cell (Undifferentiated) Carcinoma
11.2.2.Squamous Cell (Epidermoid) Carcinoma
11.2.3.Adenocarcinoma
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Non Small Cell Lung Cancer Nsclc Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Microtubule Stabilizer
12.1.2.Angiogenesis Inhibitors
12.1.3.Kinase Inhibitor
12.1.4.Epidermal Growth Factor Receptor Blocker
12.1.5.PD-1/ PD-L1 Inhibitor
12.1.6.Folate Antimetabolites
12.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Large Cell (Undifferentiated) Carcinoma
12.2.2.Squamous Cell (Epidermoid) Carcinoma
12.2.3.Adenocarcinoma
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Non Small Cell Lung Cancer Nsclc Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Microtubule Stabilizer
13.1.2.Angiogenesis Inhibitors
13.1.3.Kinase Inhibitor
13.1.4.Epidermal Growth Factor Receptor Blocker
13.1.5.PD-1/ PD-L1 Inhibitor
13.1.6.Folate Antimetabolites
13.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Large Cell (Undifferentiated) Carcinoma
13.2.2.Squamous Cell (Epidermoid) Carcinoma
13.2.3.Adenocarcinoma
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Bristol-Myers Squibb (U.S)
14.2.2.AstraZeneca plc (U.K)
14.2.3.Celgene Corporation (U.S)
14.2.4.Boehringer Ingelheim (Germany)
14.2.5.Novartis AG (Switzerland)
14.2.6.Pfizer, Inc. (U.S)
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Bristol-Myers Squibb
  • AstraZeneca plc
  • Celgene Corporation
  • Boehringer Ingelheim
  • Novartis AG
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Roche
  • Merck & Co.
  • Agennix AG

Related Industry Reports

AKT Inhibitors Market

BCR-ABL Tyrosine Kinase Inhibitor Insights

Urothelial Carcinoma Treatment Market

Food Stabilizers Market